Chicago Trust Co Na Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Chicago Trust Co Na reduced its stake in Abbott Laboratories by 0.29% during the most recent quarter end. The investment management company now holds a total of 150,843 shares of Abbott Laboratories which is valued at $6,318,813 after selling 439 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 8, 2016.Abbott Laboratories makes up approximately 2.67% of Chicago Trust Co Na’s portfolio.

Other Hedge Funds, Including , Hollencrest Securities boosted its stake in ABT in the latest quarter, The investment management firm added 1,941 additional shares and now holds a total of 20,877 shares of Abbott Laboratories which is valued at $874,538. Abbott Laboratories makes up approx 0.14% of Hollencrest Securities’s portfolio.Washington Trust Bank boosted its stake in ABT in the latest quarter, The investment management firm added 386 additional shares and now holds a total of 7,872 shares of Abbott Laboratories which is valued at $329,758. Abbott Laboratories makes up approx 0.08% of Washington Trust Bank’s portfolio.Curian Capital reduced its stake in ABT by selling 127,325 shares or 64.07% in the most recent quarter. The Hedge Fund company now holds 71,412 shares of ABT which is valued at $2,991,449. Abbott Laboratories makes up approx 0.21% of Curian Capital’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.57% at $41.97 with 79,20,234 shares getting traded on Wednesday. Post opening the session at $42.24, the shares hit an intraday low of $41.85 and an intraday high of $42.515 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.